POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out? INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Tennessee Rheumatology Society (TRS) Annual Meeting, Rheumatology Winter Clinical Symposium (RWCS), Rheumatology Association of Iowa (RAI) Annual Meeting, State of Texas of Association of Rheumatologists (STAR), Annual Basic and Clinical Immunology for the Busy Clinician, Wisconsin Rheumatology Association (WRA) Annual Meeting, Cleveland Society of Rheumatology Annual Review of Rheumatic Disease, American College of Allergy, Asthma & Immunology, Interdisciplinary Autoimmune Summit (IAS). Lu E, et al. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. Initiating Mepolizumab. Information Database, Vaccine Temperature POSTER: Real-World Patterns and Predictors of First-Line Maintenance Use Among Patients with Newly Diagnosed Advanced Ovarian Cancer: Is There an Opportunity for Change? P805; Abstract A7742]. POSTER: Impact of Residual Disease on Outcomes in Patients with Ovarian Cancer: A Meta-analysis, 5. 1053; Abstract A5058]. GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL. Visit our Rheumatology virtual scientific booth to explore our pipeline and learn Patient Experience Information (PEI) and Patient Involvement in Health Technology Assessment (HTA) Processes in 7 European Countries Using Immuno-Oncology Examples: How Can the Patient Voice Make an Impact? GSK is investigating a PI3K inhibitor, GSK2636771, in combination with enzalutamide, in PTEN-deficient metastatic castration-resistant prostate cancer (mCRPC). POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. P0017. 2. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. 10. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. 4. Welcome to AbbVie U.S. Medical Affairs This site is intended for U.S. Healthcare Professionals only. Note: The search will retrieve any scientific documents from the medical information database where the search terms match either the title or content of the document. Effect of Belimumab on Autoantibodies, Complement and B cell Subsets in Patients with Lupus Nephritis, 4. Singh AK, et al. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. 1. and Physicians? Visit our Rheumatology Virtual Booth Visit our Rheumatology virtual scientific booth to explore our pipeline and learn about disease states including Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-cell?driven antitumor immunity. ORAL PRESENTATION: Shapiro A, et al. POSTER: Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study, 7. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study. PO0465, ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. ORAL PRESENTATION: Kohli A, et al. P1454. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 ? This content is intended for personal, educational purposes only. 2015;16(9):21138-21152. 2017;3(4):294-301. Initiating Mepolizumab. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. Cost-effectiveness evaluation of sotrovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in patients at high risk of disease progression. 12. P574]. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. The information provided on this website is for informational purposes and is not intended to promote the use of any product. P154]. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. Prazma C, Bernstein D, Brightling C, et al. Stability Calculator, Contact Int J Mol Sci. P1286; Abstract A6579]. Dransfield MT, Halpin DMG, Han MK, et al. ?Trap?/Anti-PD-L1 Fusion Protein, Belantamab Mafodotin - Anti-BCMA Immunoconjugate, PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715). 5. Oncoimmunology. 10. Silver J, Bogart M, Molfino N, et al. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. The Med Affairs Network is designed to help allow medical affairs professionals to share and learn from other professionals how to advance their organizations towards excellence. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility. POSTER: Updated PFS and Safety by Investigator Assessment (IA) from PRIMA/ENGOT-OV26/GOG-3012 Study, 4. NL8095.75.000.B.01, 777 Scudders Mill Road PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14, 1. 7. 1. P1481. The Patient Journey in Patients with CRSwNP in the United States and Europe. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. PUBLICATION ONLY: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Baseline Characteristics. [Poster No. 1. Denmark POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs, 12. Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 5. 2. Plain Language Summary [HCP USE ONLY]: The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-Analysis, 15. Articles are listed in most recent order by clinical target. Goodall E, Wood R, Numbere B, et al. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. Singh AK, et al. [Abstract/Poster No. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs). PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States, 1. [Poster No. 1. Hosking L, Yeo A, Hoffman J, et al. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. Plainsboro, NJ 08536 Influence of Baseline Total IgE and History of Previous Omalizumab Use on the Impact of Mepolizumab in Reducing Rate of Severe Asthma Exacerbations: Results From the Real-World REALITI-A Study. [Abstract/Poster No. The Impact of Baseline Exhaled Nitric Oxide Levels and Blood Eosinophil Count on Clinical Outcomes in REALITI-A. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1?specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Hwee J, Smith S, Small M, et al. Nat Med. Cancer Cell.2019;36(1):100-114. Strezova A et al. Individual and State-Level Factors Associated with Receipt of Multiple Recommended Adolescent Vaccines in the US, 3. AbbVie is Lymphocyte activation gene-3 (LAG-3) negatively regulates T-cell activity and, in combination with PD-1, mediates T-cell exhaustion. Keir HR, Richardson H, Mayhew D, et al. Bogart M, Bengtson L, Rothnie K, et al. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. Encore: Open-label Pilot Study of Genetically Engineered NY-ESO-1?Specific T Cells (GSK3377794) Alone or in Combination With Pembrolizumab in Relapsed/Refractory Multiple Myeloma [Publication only], Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer, 1. PO2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. POSTER: First-line (1L) Maintenance Therapy with Niraparib + Pembrolizumab vs Placebo + Pembrolizumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): Phase 3 ZEAL-1L Study, 4. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma, 13. P713; Abstract A1828], 10. Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. 2017;31(2):101-126. This site is intended for US Healthcare Professionals. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. [Poster No. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Nave Head and Neck Squamous Cell Carcinoma (HNSCC), 17. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. The Clinical Benefit of Mepolizumab Treatment Is Independent of Baseline Maintenance Oral Corticosteroid Use: Results From the Real-World REALITI-A Study. POSTER: Analysis of anti-tumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial, 7. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines, 1. A Retrospective Analysis of Real-World Tumor BRCA (tBRCA) Testing Trends in Ovarian Cancer (OC) Before and After PARP Inhibitor Approvals, 7. Uppsalalaan 15 PO1437, 2. If you are an 3508 AD Utrecht Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Singh AK, et al. O?Connor BP, Raman VS, Erikson LD, et al. 4. 710; Abstract A1825]. POSTER: Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-? 4. Pharma reconsidering their strategies in the post-pandemic period: Medical Affairs work-frame, taking into account the new-normal situation. [Abstract/Presentation No. Congresses & Publications. This paper explores the Medical Affairs-based medical insights function and and identifies basic operational elements required to establish medical insights as a core strategic MA function. Patient Characteristics and Treatment Patterns of Elderly Asthma Patients Initiating FF/UMEC/VI. 5. [Poster No. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. and/or LAGE-1a?positive cancers. This link will take you to a website that is not owned or controlled by Genmab A/S. United Therapeutics does not provide medical advice. Poster presented at: The European Society for Medical Oncology Annual Congress; October 19-23, 2018; Munich, Germany: Poster 1840P. Blake SJ, Stannard K, Liu J, et al. 7. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. 1. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 ? Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, 4. ORAL PRESENTATION: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 1. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Poster No. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. [Poster No. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. 2016;532(7598):245-249. Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer, Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM), Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics, Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers, 1. NY-ESO-1?specific TCR?engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. 3. This site is intended for US healthcare professionals only. Dawson M, Stein EM, Huntly BJP, et al. Oral Corticosteroid?Sparing Effect of Mepolizumab in Patients With Eosinophilic Granulomatosis With Polyangiitis. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. Seifert L, Werba G, Tiwari S, et al. Tokyo 107-6235 PD-L1 is expressed by many tumor types and is linked to poor clinical outcomes in a variety of cancers. Pavord ID, Fowler A, Kerstjens HA, et al. 2. 1. Targeting B-cell maturation antigen in multiple myeloma. Poster No. POSTER: A report of the postmarketing spontaneous safety data over 24 years for GSK?s measles-mumps-rubella (MMR) vaccine. POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. 817; Abstract A4306]. Zejula [summary of product characteristics]. Stability Calculator, Click here if you are not a US Healthcare Professional, Patient, or Caregiver. They synthesize information and translate findings about therapeutics/drugs into language that can be better understood by company staff whose primary expertise is not scientific. 3. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. We provide communications and marketing expertise, counsel and resources for the School of Medicine community.
Super Mario Sunshine Bowser, Mode Of Exponential Distribution, No Transform Named String Found, Best Lightweight Sneakers For Travel, Establishing Residency In Canada,